Developer docs
API playgroundTry for free, no card

Search company profiles

Neurotech

Full company profile

uuid0003s1k

Namestring
Neurotech
Legal namestring
Neurotech Pharmaceuticals, Inc.
Company typeenum
Private
Founded yearint
1995
Descriptiontext

Neurotech Pharmaceuticals, Inc. is a privately-held biotechnology company founded in 1995 and headquartered in Cumberland, Rhode Island, with a commercial office in Needham, Massachusetts, and 51-100 employees. The company develops sight-saving therapeutics for chronic retinal diseases, with its sole FDA-approved product, ENCELTO (revakinagene taroretcel-lwey), approved in March 2025 as the first and only treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a rare bilateral retinal disease causing progressive photoreceptor loss and central vision impairment.

The company's core technology is its proprietary Encapsulated Cell Therapy (ECT) platform, which encapsulates genetically engineered human retinal cells within a semi-permeable membrane. Once implanted in the vitreous, the capsule creates an immune-protective microenvironment and continuously secretes Ciliary Neurotrophic Factor (CNTF) — a well-studied neuroprotective protein — directly to the retina for greater than two years from a single surgical application. This sustained-delivery architecture differentiates ENCELTO from conventional intravitreal or sub-retinal injection therapies that require frequent re-administration. The platform is supported by Orphan-Drug Designation (2012), Fast Track Designation (2018), Priority Review (2024), and a permanent reimbursement J-Code (J3403, effective October 1, 2025).

Neurotech operates a specialty pharmaceutical commercial model, selling ENCELTO directly to trained retina specialists via field sales representatives, medical science liaisons, and field reimbursement directors, with distribution through physician-administered specialty channels in the United States only. The company is controlled by the Lowy family, with a Board including former Johnson & Johnson CEO Alex Gorsky (Lead Director) and Wilmer Eye Institute Director Peter J. McDonnell, M.D. Revenue derives entirely from ENCELTO product sales at premium orphan-drug pricing levels, and the company has historically funded operations through venture financing, including a $35 million round in 2006 led by Burrill & Company.

Short descriptiontext

Neurotech Pharmaceuticals is a private biotech that developed ENCELTO, the first FDA-approved encapsulated cell therapy for Macular Telangiectasia Type 2 (MacTel), delivering sustained Ciliary Neurotrophic Factor via a single intraocular implant to protect photoreceptors in adult patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCumberland, United States
HQ citystring
Cumberland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy implants, retinal therapeutics, ophthalmic biotechnology, encapsulated cell therapy, rare disease drugs
Industry3 codes
PRIMARYHLAHAIAH
Infusion Sets, Catheters & Pump Consumables
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAK
Ophthalmic Regeneration (cornea/retina)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Ophthalmic Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from the sale of ENCELTO (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia Type 2 (MacTel). The product is administered via a surgical procedure and likely commands premium pricing as a novel cell therapy for a rare disease with no prior approved treatments.

neurotechpharmaceuticals.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1ENCELTO
Description

FDA-approved treatment for Macular Telangiectasia Type 2 (MacTel), also known by its generic name revakinagene taroretcel-lwey

neurotechpharmaceuticals.com
Core offering1 text field

Neurotech Pharmaceuticals develops and commercializes ENCELTO (revakinagene taroretcel-lwey), an FDA-approved encapsulated cell therapy implant for treating adults with idiopathic Macular Telangiectasia Type 2 (MacTel). The product is built on the company's proprietary Encapsulated Cell Therapy (ECT) Platform, which encapsulates genetically engineered human retinal cells within a semi-permeable membrane to continuously deliver Ciliary Neurotrophic Factor (CNTF) to the retina for greater than two years from a single surgical implantation. ENCELTO is the first and only FDA-approved treatment for MacTel Type 2, a rare bilateral retinal disease causing progressive photoreceptor loss and central vision impairment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • First FDA-approved treatment for MacTel Type 2
+2 more records
Product overview1 text field

Neurotech Pharmaceuticals is a private biotech company developing a singleFDA-approved product, ENCELTO (revakinagene taroretcel-lwey), delivered via its proprietary Encapsulated Cell Therapy (ECT) platform. The ECT platform is a cell-based drug delivery technology that encapsulates genetically engineered human retinal cells within a semi-permeable membrane, enabling sustained, long-term delivery of therapeutic proteins (specifically Ciliary Neurotrophic Factor, or CNTF) to the retina. ENCELTO is indicated for the treatment of adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a chronic retinal disease. The therapy is administered via a single intraocular implant designed to deliver CNTF for greater than two years following a single application.

Product and service1 record
1ENCELTO (revakinagene taroretcel-lwey)
CategoryOphthalmic Biopharmaceuticals / Cell Therapy
Description

ENCELTO is an FDA-approved encapsulated cell therapy implant indicated for the treatment of adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a rare bilateral retinal disease causing progressive loss of central vision. The implant contains genetically engineered human retinal cells encapsulated within a semi-permeable membrane that continuously secretes Ciliary Neurotrophic Factor (CNTF) into the vitreous, with the goal of slowing photoreceptor loss and disease progression for greater than two years following a single intraocular surgical implantation.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeOthers
Description

Patient advocacy organization providing community resources and support for patients with eye diseases. Neurotech references this organization as a community resource for MacTel patients.

Strategic tierMinorTypeOthers
Description

Rare disease advocacy organization providing support and resources for patients with rare conditions including MacTel. Listed as a community resource for patients.

Strategic tierMinorTypeOthers
Description

Nonprofit dedicated to research for treatments and cures for blinding retinal diseases. Listed as a community resource for MacTel patients.

4American Academy of Ophthalmology
Strategic tierMinorTypeOthers
Description

Professional medical association for ophthalmologists. Listed as a community resource for patient education on eye health.

neurotechpharmaceuticals.com
Strategic tierMinorTypeOthers
Description

Organization providing services and support for blind and visually impaired individuals. Listed as a community resource for MacTel patients.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Retinal disease biotech (acquired by Astellas in 2023) with FDA-approved therapy for geographic atrophy. Comparable to Neurotech as a commercialized retinal therapeutics company; now part of a larger strategic owner.

TypeEmerging player
Description

Clinical-stage gene therapy company with capabilities in ocular gene therapy (e.g., AAV-RPGR for X-linked retinitis pigmentosa) and in-house GMP manufacturing. Comparable to Neurotech in deploying novel genetic and cell-based therapeutics to the eye.

TypeDirect peer
Description

Commercial-stage biotech developing therapeutics for retinal diseases (geographic atrophy, AMD). Comparable to Neurotech as a recently commercialized, specialty ophthalmology biotech targeting retinal indications with novel mechanisms.

TypeEmerging player
Description

Clinical-stage gene therapy company developing single-administration intravitreal therapies for wet AMD and diabetic retinopathy. Comparable to Neurotech in deploying novel ocular drug-delivery modalities for chronic retinal disease.

TypeEmerging player
Description

Clinical-stage gene therapy company developing neuroprotective therapies for retinal degenerative diseases (e.g., Leber hereditary optic neuropathy). Comparable in deploying novel ocular therapeutics for rare retinal/optic nerve indications.

TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic cell transplants for ophthalmology, neurology, and oncology. Directly comparable to Neurotech's ECT platform in using encapsulated or transplanted cells to deliver therapeutic proteins to retinal tissue.

TypeBroad incumbent
Description

Gene therapy company (acquired by Novartis in 2022) focused on geographic atrophy and inherited retinal diseases. Comparable as a retinal-disease biotech using novel delivery modalities; larger strategic owner now provides competitive context.

TypeEmerging player
Description

Clinical-stage RNA therapeutics company targeting inherited retinal diseases such as Leber congenital amaurosis and retinitis pigmentosa. Comparable in developing novel modalities for rare, vision-threatening retinal indications.

TypeEmerging player
Description

Gene therapy company with FDA-approved ocular gene therapy (ABBV-RGX-314 partnership with AbbVie) for wet AMD and diabetic retinopathy. Comparable as a developer of novel one-time ocular therapeutics for retinal disease.

TypeDirect peer
Description

Clinical-stage retinal therapeutics company developing novel biological agents (antibody biopolymer conjugates) for retinal vascular and inflammatory diseases. Comparable as a venture-backed biotech focused on innovative retinal drug delivery and ophthalmology indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neurotech

Ophthalmic Biopharmaceuticalsneurotechpharmaceuticals.com

Neurotech Pharmaceuticals is a private biotech that developed ENCELTO, the first FDA-approved encapsulated cell therapy for Macular Telangiectasia Type 2 (MacTel), delivering sustained Ciliary Neurotrophic Factor via a single intraocular implant to protect photoreceptors in adult patients.

What Neurotech does

Neurotech Pharmaceuticals, Inc. is a privately-held biotechnology company founded in 1995 and headquartered in Cumberland, Rhode Island, with a commercial office in Needham, Massachusetts, and 51-100 employees. The company develops sight-saving therapeutics for chronic retinal diseases, with its sole FDA-approved product, ENCELTO (revakinagene taroretcel-lwey), approved in March 2025 as the first and only treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a rare bilateral retinal disease causing progressive photoreceptor loss and central vision impairment.

The company's core technology is its proprietary Encapsulated Cell Therapy (ECT) platform, which encapsulates genetically engineered human retinal cells within a semi-permeable membrane. Once implanted in the vitreous, the capsule creates an immune-protective microenvironment and continuously secretes Ciliary Neurotrophic Factor (CNTF) — a well-studied neuroprotective protein — directly to the retina for greater than two years from a single surgical application. This sustained-delivery architecture differentiates ENCELTO from conventional intravitreal or sub-retinal injection therapies that require frequent re-administration. The platform is supported by Orphan-Drug Designation (2012), Fast Track Designation (2018), Priority Review (2024), and a permanent reimbursement J-Code (J3403, effective October 1, 2025).

Neurotech operates a specialty pharmaceutical commercial model, selling ENCELTO directly to trained retina specialists via field sales representatives, medical science liaisons, and field reimbursement directors, with distribution through physician-administered specialty channels in the United States only. The company is controlled by the Lowy family, with a Board including former Johnson & Johnson CEO Alex Gorsky (Lead Director) and Wilmer Eye Institute Director Peter J. McDonnell, M.D. Revenue derives entirely from ENCELTO product sales at premium orphan-drug pricing levels, and the company has historically funded operations through venture financing, including a $35 million round in 2006 led by Burrill & Company.

Neurotech firmographics

Firmographics
Name
Neurotech
Legal name
Neurotech Pharmaceuticals, Inc.
Website
https://neurotechpharmaceuticals.com
Company type
Private
Founded year
1995
Operating status
Operating
Headcount range
101–250 employees
Short description
Neurotech Pharmaceuticals is a private biotech that developed ENCELTO, the first FDA-approved encapsulated cell therapy for Macular Telangiectasia Type 2 (MacTel), delivering sustained Ciliary Neurotrophic Factor via a single intraocular implant to protect photoreceptors in adult patients.
Ownership category
akta.pro rank

Neurotech industry classification

Industry
Product category
Ophthalmic Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAIAH
Infusion Sets, Catheters & Pump Consumables
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAK
Ophthalmic Regeneration (cornea/retina)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Cell therapy implants
  • Retinal therapeutics
  • Ophthalmic biotechnology
  • Encapsulated cell therapy
  • Rare disease drugs

Where Neurotech is headquartered

Location

Headquarters

HQ city
Cumberland
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Neurotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Revenue from the sale of ENCELTO (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia Type 2 (MacTel). The product is administered via a surgical procedure and likely commands premium pricing as a novel cell therapy for a rare disease with no prior approved treatments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Neurotech product offering

Product offering

Core offering

Neurotech Pharmaceuticals develops and commercializes ENCELTO (revakinagene taroretcel-lwey), an FDA-approved encapsulated cell therapy implant for treating adults with idiopathic Macular Telangiectasia Type 2 (MacTel). The product is built on the company's proprietary Encapsulated Cell Therapy (ECT) Platform, which encapsulates genetically engineered human retinal cells within a semi-permeable membrane to continuously deliver Ciliary Neurotrophic Factor (CNTF) to the retina for greater than two years from a single surgical implantation. ENCELTO is the first and only FDA-approved treatment for MacTel Type 2, a rare bilateral retinal disease causing progressive photoreceptor loss and central vision impairment.

Product overview

Neurotech Pharmaceuticals is a private biotech company developing a singleFDA-approved product, ENCELTO (revakinagene taroretcel-lwey), delivered via its proprietary Encapsulated Cell Therapy (ECT) platform. The ECT platform is a cell-based drug delivery technology that encapsulates genetically engineered human retinal cells within a semi-permeable membrane, enabling sustained, long-term delivery of therapeutic proteins (specifically Ciliary Neurotrophic Factor, or CNTF) to the retina. ENCELTO is indicated for the treatment of adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a chronic retinal disease. The therapy is administered via a single intraocular implant designed to deliver CNTF for greater than two years following a single application.

Differentiator

Problem solved

Functional benefit

Brands

  • ENCELTO: FDA-approved treatment for Macular Telangiectasia Type 2 (MacTel), also known by its generic name revakinagene taroretcel-lwey

Products and services

  • ENCELTO (revakinagene taroretcel-lwey) ENCELTO is an FDA-approved encapsulated cell therapy implant indicated for the treatment of adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a rare bilateral retinal disease causing progressive loss of central vision. The implant contains genetically engineered human retinal cells encapsulated within a semi-permeable membrane that continuously secretes Ciliary Neurotrophic Factor (CNTF) into the vitreous, with the goal of slowing photoreceptor loss and disease progression for greater than two years following a single intraocular surgical implantation.

Quantifiable outcome

  • First FDA-approved treatment for MacTel Type 2
  • +2 more outcomes

Companies that use Neurotech

Customer profile

Segments1 record

Ideal customer profiles1 record

Neurotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Neurotech partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor.

  • Prevent BlindnessminorOthersPatient advocacy organization providing community resources and support for patients with eye diseases. Neurotech references this organization as a community resource for MacTel patients.
  • National Organization for Rare Disorders (NORD)minorOthersRare disease advocacy organization providing support and resources for patients with rare conditions including MacTel. Listed as a community resource for patients.
  • Foundation Fighting BlindnessminorOthersNonprofit dedicated to research for treatments and cures for blinding retinal diseases. Listed as a community resource for MacTel patients.
  • American Academy of OphthalmologyminorOthersProfessional medical association for ophthalmologists. Listed as a community resource for patient education on eye health.
  • The Carroll Center for the BlindminorOthersOrganization providing services and support for blind and visually impaired individuals. Listed as a community resource for MacTel patients.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Neurotech competitors and assessment

Company assessment

Broad incumbents

  • Iveric Bio (Astellas): Retinal disease biotech (acquired by Astellas in 2023) with FDA-approved therapy for geographic atrophy. Comparable to Neurotech as a commercialized retinal therapeutics company; now part of a larger strategic owner.
  • Gyroscope Therapeutics (Novartis): Gene therapy company (acquired by Novartis in 2022) focused on geographic atrophy and inherited retinal diseases. Comparable as a retinal-disease biotech using novel delivery modalities; larger strategic owner now provides competitive context.

Emerging players

  • MeiraGTx Holdings: Clinical-stage gene therapy company with capabilities in ocular gene therapy (e.g., AAV-RPGR for X-linked retinitis pigmentosa) and in-house GMP manufacturing. Comparable to Neurotech in deploying novel genetic and cell-based therapeutics to the eye.
  • Adverum Biotechnologies: Clinical-stage gene therapy company developing single-administration intravitreal therapies for wet AMD and diabetic retinopathy. Comparable to Neurotech in deploying novel ocular drug-delivery modalities for chronic retinal disease.
  • GenSight Biologics: Clinical-stage gene therapy company developing neuroprotective therapies for retinal degenerative diseases (e.g., Leber hereditary optic neuropathy). Comparable in deploying novel ocular therapeutics for rare retinal/optic nerve indications.
  • ProQR Therapeutics: Clinical-stage RNA therapeutics company targeting inherited retinal diseases such as Leber congenital amaurosis and retinitis pigmentosa. Comparable in developing novel modalities for rare, vision-threatening retinal indications.
  • REGENXBIO: Gene therapy company with FDA-approved ocular gene therapy (ABBV-RGX-314 partnership with AbbVie) for wet AMD and diabetic retinopathy. Comparable as a developer of novel one-time ocular therapeutics for retinal disease.

Direct peers

  • Apellis Pharmaceuticals: Commercial-stage biotech developing therapeutics for retinal diseases (geographic atrophy, AMD). Comparable to Neurotech as a recently commercialized, specialty ophthalmology biotech targeting retinal indications with novel mechanisms.
  • Lineage Cell Therapeutics: Clinical-stage cell therapy company developing allogeneic cell transplants for ophthalmology, neurology, and oncology. Directly comparable to Neurotech's ECT platform in using encapsulated or transplanted cells to deliver therapeutic proteins to retinal tissue.
  • Kodiak Sciences: Clinical-stage retinal therapeutics company developing novel biological agents (antibody biopolymer conjugates) for retinal vascular and inflammatory diseases. Comparable as a venture-backed biotech focused on innovative retinal drug delivery and ophthalmology indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Neurotech social profiles

Digital presence

Neurotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neurotech leadership team

Management profile

Number of profiles

Profiles12 records

Neurotech funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neurotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurotech

What does Neurotech do?

Neurotech Pharmaceuticals develops and commercializes ENCELTO (revakinagene taroretcel-lwey), an FDA-approved encapsulated cell therapy implant for treating adults with idiopathic Macular Telangiectasia Type 2 (MacTel). The product is built on the company's proprietary Encapsulated Cell Therapy (ECT) Platform, which encapsulates genetically engineered human retinal cells within a semi-permeable membrane to continuously deliver Ciliary Neurotrophic Factor (CNTF) to the retina for greater than two years from a single surgical implantation. ENCELTO is the first and only FDA-approved treatment for MacTel Type 2, a rare bilateral retinal disease causing progressive photoreceptor loss and central vision impairment.

Is Neurotech a public or private company?

Neurotech is a private company. It is classified as family owned and is currently operating.

When was Neurotech founded?

Neurotech was founded in 1995. It employs 101 to 250 people.

Where is Neurotech based?

Neurotech is headquartered in Cumberland, United States, in the North America region.

How does Neurotech make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Neurotech's main competitors?

Broad incumbents on record are Iveric Bio (Astellas) and Gyroscope Therapeutics (Novartis). Emerging players are MeiraGTx Holdings, Adverum Biotechnologies, GenSight Biologics, ProQR Therapeutics and REGENXBIO. Direct peers are Apellis Pharmaceuticals, Lineage Cell Therapeutics and Kodiak Sciences.

Does Neurotech have an API?

No public API is recorded for Neurotech.

What industry is Neurotech in?

Neurotech's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAHAIAH, Infusion Sets, Catheters & Pump Consumables, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Providence Business NewsNeurotech Pharmaceuticals purchased for $550MAlcon acquired Neurotech Pharmaceuticals for $550 million, with possible additional payments contingent on commercial achievements. The deal was announced on Oct. 20 by the Rhode Island biotech company.Pulse 2.0Alcon Acquires Neurotech Pharmaceuticals For $550 Million To Add FDA-Approved ENCELTO Retinal TherapyAlcon acquired Neurotech Pharmaceuticals for $550 million, adding ENCELTO, the first FDA-approved treatment for MacTel. The deal includes contingent payments and is expected to be accretive to net sales growth in 2027. Alcon expects the acquisition to become accretive thereafter.OcbjAlcon Acquires Neurotech Pharmaceuticals for $550MAlcon acquired Neurotech Pharmaceuticals for $550 million, adding its ENCELTO treatment to its retina portfolio. ENCELTO is the first and only FDA-approved treatment for adults with a rare, progressive retinal disease that can lead to irreversible central vision loss.Seeking AlphaAlcon acquires Neurotech PharmaceuticalsAlcon acquired privately held Neurotech Pharmaceuticals for $550 million, gaining ownership of Encelto, an encapsulated cell therapy approved in 2025. Encelto is the only treatment for idiopathic Macular Telangiectasia Type 2, affecting about 25,000 US patients. The deal may include contingent payments for commercial milestones.TradingViewAlcon acquires Neurotech PharmaceuticalsAlcon acquired privately held Neurotech Pharmaceuticals for $550 million, gaining ownership of Encelto, an encapsulated cell therapy approved in 2025. Encelto is the only treatment for idiopathic Macular Telangiectasia Type 2, affecting about 25,000 US patients. The deal may include contingent payments tied to commercial milestones.Ophthalmology TimesNeurotech Pharmaceuticals receives priority review of BLA for NT-501 for treatment of MacTelNeurotech Pharmaceuticals announced that the FDA has granted priority review for its Biologic License Application (BLA) for NT-501, a therapy for MacTel. The application has a PDUFA goal date of December 17, 2024. NT-501 is an investigational encapsulated cell therapy designed to deliver ciliary neurotrophic factor to slow retinal degeneration.Ophthalmology TimesNeurotech CCO Scott Hunter passes awayScott Hunter, Chief Commercial Officer of Neurotech Pharmaceuticals Inc., passed away on December 3, 2024. The company honored his contributions to building the commercial strategy and infrastructure during his tenure since January 2023. Hunter previously held significant roles at Novartis, Shire, and Bausch + Lomb in the eyecare sector.CGTLiveNeurotech’s Encapsulated Cell Therapy Encelto Approved by FDA for Macular Telangiectasia Type 2The FDA has approved Neurotech Pharmaceuticals' Encelto (revakinagene taroretcel-lwey) as the first treatment for adults with idiopathic macular telangiectasia type 2. The encapsulated cell therapy implant is expected to become available in the United States in June 2025.Ophthalmology TimesAAO 2023: Neurotech's encapsulated cell therapy, NT-501Neurotech CEO Rich Small presented updates on the company's encapsulated cell therapy, NT-501, at the American Academy of Ophthalmology meeting. The company reported that Phase III studies for NT-501 in treating macular telangiectasia demonstrated a significant slowing of disease progression compared to controls.pharmaphorumNeurotech's cell therapy gets FDA nod for eye disorder MacTelThe FDA has approved Neurotech Pharma's cell therapy, Encelto, as the first treatment for idiopathic macular telangiectasia type 2 (MacTel), a rare eye disorder causing progressive sight loss. The approval is based on Phase 3 trial results showing the implant significantly slowed photoreceptor loss in patients, with a planned US launch scheduled for June. This marks a significant milestone for Neurotech Pharma in the neurodegenerative retina disease sector.